Fatty Liver Index
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۱۰۰۰ • واحد: mg/dL
حداقل ۱۰ — حداکثر ۶۰ • واحد: kg/m²
حداقل ۰ — حداکثر ۱۰۰۰ • واحد: U/L
حداقل ۴۰ — حداکثر ۲۰۰ • واحد: cm
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–30
- Indeterminate Risk30–60
- High Risk60–100
The Fatty Liver Index calculates assessing gastrointestinal disease severity, endoscopic intervention urgency, and rebleeding risk. Key inputs include triglycerides. Scores guide timing emergent endoscopy, initiating high-dose proton pump inhibitor infusions, or obtaining surgical consultation. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Diagnoses fatty liver using lab and exam findings. A simple and accurate predictor of hepatic steatosis in the general population.
Clinical Indication
The Fatty Liver Index is indicated for bedside clinical practice to support Diagnoses fatty liver using lab and exam findings. A simple and accurate predictor of hepatic steatosis in the general population.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with upper or lower gastrointestinal hemorrhage, acute pancreatitis, acute liver failure, or inflammatory bowel disease. Clinical application is indicated across Endoscopy suites, emergency GI triage, acute medical floors, and hepatology services.
Limitations & Contraindications
Initial hemoglobin values in hyperacute hemorrhage may falsely appear normal prior to complete extravascular-to-intravascular fluid equilibration. Clinical exclusion: Patients with HCV, HBV, and other liver diseases were excluded from validation.
Clinical Pearls & Action Plan
Aggressive intravascular volume resuscitation and blood product support must precede diagnostic or therapeutic endoscopy. Guideline pearl: Patients with HCV, HBV, and other liver diseases were excluded from validation.
FLI = (e^y / (1 + e^y)) × 100, where y = 0.953 × ln(triglycerides) + 0.139 × BMI + 0.718 × ln(GGT) + 0.053 × waist circumference - 15.745
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| triglycerides | float | Yes | Serum triglycerides level(mg/dL) |
| bmi | float | Yes | Body Mass Index(kg/m²) |
| ggt | float | Yes | Gamma-glutamyl transpeptidase(U/L) |
| waist_circumference | float | Yes | Waist circumference measured at midpoint between lower costal margin and iliac crest(cm) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–30 | Low Risk | Fatty liver ruled out |
| 30–60 | Indeterminate Risk | Inconclusive |
| 60–100 | High Risk | Fatty liver ruled in |
Evidence-Based References (EBM)
- Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006 Nov 2;6:33.
- Cuthbertson DJ, Weickert MO, Lythgoe D, Sprung VS, Dobson R, Shoajee-Moradie F, et al. External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. Eur J Endocrinol. 2014 Nov;171(5):561-9.
- Koehler EM, Schouten JN, Hansen BE, Hofman A, Stricker BH, Janssen HL. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013 Sep;11(9):1201-4.